Objectives: To compare the safety and efficacy of low dose misoprostol and dinoprostone for cervical ripening and labor induction Methods: It was an open label randomized controlled trial conducted at department of Obstetrics & Gynecology, Dr TMA Pai Rotary Hospital, Karkala. The main outcome measure was induction-to-vaginal delivery interval. Secondary outcome measures were the labor characteristics, maternal complications and neonatal outcomes. Results: Out of 320 eligible women included for final analysis, 159 received misoprostol and 161 dinoprostone. There was no significant difference between the two groups in induction-to-vaginal delivery interval, mode of delivery, number of women delivering within 24 hours and neonatal outcomes. The efficacies of the two prostaglandins were similar. Conclusion: Low dose misoprostol is as efficient as dinoprostone in achieving active labor and delivering with in 24 hours. The maternal and neonatal outcomes associated with each group were similar. It is a cheaper alternative for labor induction.
Introduction
Situations arise in obstetrics where it becomes necessary to interrupt a pregnancy in the interest of mother or baby or both. Recently, elective inductions of labor at term have increased dramatically. Although dinoprostone gel is considered as the preferred method for labor induction, it is relatively expensive drug. The average maximum retail price is 230.50 per 0.5 mg dose of the endocervical gel (Cerviprime, AstraZeneca
The Journal of Obstetrics and Gynecology of India March / April 2011 pg 153 -160 Pharma). Dinoprostone gel also requires refrigeration for storage which can cause significant problems for maternity units. There is a growing interest on misoprostol, a prostaglandin E1 analogue for labor induction which is much cheaper and stable at room temperature. A single 100 tablet costs 8.60, thus a low dose of 25 μg dose costs approximately 2.15 Replacing dinoprostone with misoprostol would allow considerable cost savings. A large body of data exists on misoprostol for use in cervical ripening and labor induction. Vaginal application of misoprostol has been reported in over 9000 women worldwide and seems to have safety profile similar to that of dinoprostone.
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The initial trials have used much higher dose of drug. But the American College of Obstetricians and Gynecologists (ACOG) recommends the use of low dose of 25 μg vaginal misoprostol every 3 to 6 hours.
3 At present, there is only limited information available on low dose regimens (25 μg) of misoprostol for labor induction. With this background information the current trial was designed to compare the efficacy and safety of low dose of vaginal misoprostol with routinely used dinoprostone gel for induction of labor.
Material and Methods
This was a randomized controlled trial conducted from January 2006 to August 2008 at Dr TMA Pai Rotary Hospital, Karkala, a secondary level care hospital (an associated hospital of Manipal University, Manipal) in west coast of India. The objective was to compare the safety and efficacy of low dose of vaginal misoprostol with intracervical dinoprostone gel for induction of labor. The study was approved by the local institutional ethical committee. All eligible women with obstetrical or medical indication for labor induction with no contraindication for vaginal delivery were enrolled in the trial. The inclusion criteria were; singleton pregnancy, more than 37 weeks, cephalic presentation, Bishop score of five or less, amniotic fluid index of five or more, reactive fetal heart rate pattern, past dated pregnancy (period of gestation 40 weeks or more), membranes intact or ruptured. Women with following criteria were excluded from the study; para three or more, prior uterine scar (previous cesarean section and myomectomy), multiple pregnancy, estimated fetal weight more than 4000 or less than 2000 grams, abnormal fetal heart rate (FHR) tracings on non stress test (NST), placenta previa, hypersensitivity to prostaglandins, renal, hepatic or cardiovascular disease and severe asthma.
Sonography was performed to confirm the presentation expected fetal weight and amniotic fluid index. Prior to induction vaginal examination will be done to assign the Bishop's score and a NST will be routinely performed to evaluate the fetal well being. The envelopes were prepared before the start of the study. After written informed consent, women were randomized to receive either 25μg of misoprostol (quartering 100 g tablets Cytolog, Zydus Cadila) in posterior fornix of vagina or 0.5 mg of l dinoprostone gel intracervically (Cerviprime, AstraZeneca Pharma). The dose was repeated if necessary every six hourly to a maximum of three doses in 24 hours.
The allocation of treatment was done by block randomization. Blocks of ten were prepared at the beginning of the trial and assignment was concealed by placement in consecutively numbered sealed envelopes. These were drawn in a consecutive order by the doctor, who was unaware of the agent to be allocated until the envelope was opened. The study was not placebo controlled therefore women and doctors were aware of the treatment allocated. Women lay down for at least 30 minutes after induction. Pelvic examination was repeated after six and twelve hours of insertion of drug or earlier when clinically indicated to assess the cervical score. Continuous electronic fetal heart rate monitoring was performed in all patients in active labor. Labor was augmented with oxytocin in patients with arrest of cervical dilatation due to poor contractions. Augmentation was delayed for six hours after administration of drug. Artificial rupture of the membranes was performed when clinically indicated.
Labor induction was considered successful if vaginal delivery occurred within 24 hours of induction. A primary outcome measure was the interval from first dose of drug to vaginal delivery. Secondary outcome variables included; change in Bishop score at six and twelve hours, time interval from induction to onset of adequate uterine contractions (three contractions per ten minutes), mode and route of delivery, indications for cesarean delivery, number of emergency cesareans performed for abnormal FHR pattern, number of doses of drugs used, oxytocin augmentation, incidence of adverse effects; uterine contraction abnormalities, pattern of FHR abnormalities. Specific prostaglandin side effects such as hyperpyrexia, vomiting and diarrhea, incidence of postpartum hemorrhage, cervical tears, and vaginal tears were recorded. The variables in neonatal outcome included birth weight, APGAR score at 1 and 5 min, incidence of meconium stained amniotic fluid, admission to neonatal intensive care unit. The patient's satisfaction of induction of labor was also recorded. Statistical analysis of data was performed using SPSS version 16. Variables were analyzed with chi-square test or Mann-Whitney's test, Fisher exact t test, and student t-test. The P value < 0.05 was considered as significant.
Results
Out of 320 eligible women included for final analysis 159 were received misoprostol and 161 dinoprostone. There was one incidence of violation of protocol, one woman inadvertently received dinoprostone instead of allocated 25μg misoprostol. No women were lost to follow up. The demographic characteristics of the women and indications for induction of labor in both groups were comparable (Table1). There is no
